Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram.

Chen TC, Chan N, Labib S, Yu J, Cho HY, Hofman FM, Schönthal AH.

Int J Mol Sci. 2018 Jan 17;19(1). pii: E277. doi: 10.3390/ijms19010277.

2.

The Role of Protein Kinase B Signaling Pathway in Anti-Cancer Effect of Rolipram on Glioblastoma Multiforme: An In Vitro Study.

Ramezani S, Hadjighassem M, Vousooghi N, Parvaresh M, Arbabi F, Amini N, Joghataei MT.

Basic Clin Neurosci. 2017 Jul-Aug;8(4):325-336. doi: 10.18869/nirp.bcn.8.4.325.

3.

Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.

Cao B, Wang K, Liao JM, Zhou X, Liao P, Zeng SX, He M, Chen L, He Y, Li W, Lu H.

Elife. 2016 Jul 7;5. pii: e15978. doi: 10.7554/eLife.15978.

4.

The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis.

Rao R, Salloum R, Xin M, Lu QR.

Cell Cycle. 2016 May 18;15(10):1325-30. doi: 10.1080/15384101.2016.1164371. Review.

5.

Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.

Nagy Z, Baghy K, Hunyadi-Gulyás É, Micsik T, Nyírő G, Rácz G, Butz H, Perge P, Kovalszky I, Medzihradszky KF, Rácz K, Patócs A, Igaz P.

Am J Cancer Res. 2015 Nov 15;5(12):3645-58. eCollection 2015.

6.

Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions.

Sengupta R, Barone A, Marasa J, Taylor S, Jackson E, Warrington NM, Rao S, Kim AH, Leonard JR, Piwnica-Worms D, Rubin JB.

Oncotarget. 2015 Jul 30;6(21):18282-92.

7.

Targeting brain tumor cAMP: the case for sex-specific therapeutics.

Warrington NM, Sun T, Rubin JB.

Front Pharmacol. 2015 Jul 28;6:153. doi: 10.3389/fphar.2015.00153. eCollection 2015.

8.

Not so Fast: Co-Requirements for Sonic Hedgehog Induced Brain Tumorigenesis.

Ward SA, Rubin JB.

Cancers (Basel). 2015 Aug 6;7(3):1484-98. doi: 10.3390/cancers7030848. Review.

9.

Ionizing radiation-induced foci persistence screen to discover enhancers of accelerated senescence.

Labay E, Efimova EV, Quarshie BK, Golden DW, Weichselbaum RR, Kron SJ.

Int J High Throughput Screen. 2011 Mar;2:1-13.

10.

An integrative view on sex differences in brain tumors.

Sun T, Plutynski A, Ward S, Rubin JB.

Cell Mol Life Sci. 2015 Sep;72(17):3323-42. doi: 10.1007/s00018-015-1930-2. Epub 2015 May 19. Review.

11.

An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition.

Williams CH, Hempel JE, Hao J, Frist AY, Williams MM, Fleming JT, Sulikowski GA, Cooper MK, Chiang C, Hong CC.

Cell Rep. 2015 Apr 7;11(1):43-50. doi: 10.1016/j.celrep.2015.03.001. Epub 2015 Mar 26.

12.

PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.

Brooks MD, Jackson E, Warrington NM, Luo J, Forys JT, Taylor S, Mao DD, Leonard JR, Kim AH, Piwnica-Worms D, Mitra RD, Rubin JB.

PLoS One. 2014 Sep 9;9(9):e107397. doi: 10.1371/journal.pone.0107397. eCollection 2014.

13.

Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule.

Kang TW, Choi SW, Yang SR, Shin TH, Kim HS, Yu KR, Hong IS, Ro S, Cho JM, Kang KS.

Sci Rep. 2014 Jul 3;4:5546. doi: 10.1038/srep05546.

14.

Targeted activation of PKA and Epac promotes glioblastoma regression in vitro.

Sugimoto N, Miwa S, Tsuchiya H, Hitomi Y, Nakamura H, Yachie A, Koizumi S.

Mol Clin Oncol. 2013 Mar;1(2):281-285. Epub 2013 Jan 14.

15.

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

Cefalo G, Massimino M, Ruggiero A, Barone G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garrè ML, Perilongo G, Madon E, Colosimo C, Riccardi R.

Neuro Oncol. 2014 May;16(5):748-53. doi: 10.1093/neuonc/not320. Epub 2014 Jan 30.

16.

Identification of novel genetic alterations in samples of malignant glioma patients.

Milinkovic V, Bankovic J, Rakic M, Stankovic T, Skender-Gazibara M, Ruzdijic S, Tanic N.

PLoS One. 2013 Dec 16;8(12):e82108. doi: 10.1371/journal.pone.0082108. eCollection 2013.

17.

Clinical and molecular genetics of the phosphodiesterases (PDEs).

Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA.

Endocr Rev. 2014 Apr;35(2):195-233. doi: 10.1210/er.2013-1053. Epub 2013 Dec 5. Review.

18.

Protein kinase a in cancer.

Caretta A, Mucignat-Caretta C.

Cancers (Basel). 2011 Feb 28;3(1):913-26. doi: 10.3390/cancers3010913.

19.

Regulation of the Hippo pathway and implications for anticancer drug development.

Park HW, Guan KL.

Trends Pharmacol Sci. 2013 Oct;34(10):581-9. doi: 10.1016/j.tips.2013.08.006. Epub 2013 Sep 16. Review.

20.

Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.

Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6109-14. doi: 10.1073/pnas.1218206110. Epub 2013 Mar 27.

Supplemental Content

Support Center